Abstract Respiratory syncytial virus (RSV) is the leading global cause of serious respiratory disease in infants and an important respiratory pathogen in older adults. The RSV prefusion F protein (preF) is a major target of neutralizing antibodies shown to protect against RSV disease. The bivalent preF protein subunit vaccine (RSVpreF; Abrysvo®) contains stabilized preF antigens representing the two major RSV subgroups, RSV A and RSV B.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Katrina E.
Contact Katrina E., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack